New Tool: ProSource
Check out our packaging and processing solutions finder, ProSource.

Biological drugs market to 2020

Downloadable report analyzes growth factors and restraints for biological drugs from 2014 to 2020, using 2013 as a baseline.

Downloadable report analyzes growth factors and restraints for biological drugs from 2014 to 2020, using 2013 as a baseline.
Downloadable report analyzes growth factors and restraints for biological drugs from 2014 to 2020, using 2013 as a baseline.

Report Buyer, an industry intelligence source of market research, provides in-depth analysis and estimation of the biological drugs market from 2014 to 2020, in a new downloadable report

Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, autoimmune diseases, and other medical disorders. Biological drugs include therapeutic proteins, monoclonal antibody (mAb), and vaccines. The biological drugs market is growing due to the increasing prevalence of chronic diseases and the demand for biological drugs is growing due to the increase in the global geriatric population. Moreover, various government associations are also supporting in growth of biological drugs market. Furthermore, advancement in biomedical sciences holds immense potential for the growth of the biologic drugs market.

On the other hand, the high cost of biologic drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, the risk of adverse effects associated with biologic injectable drugs is also one of the key restraints of the biological drugs market.

Data pertaining to current market dynamics including market drivers, restraints, trends, and recent developments has been provided in the biological drugs market report. The global biological drugs market is categorized based on therapeutic protein, monoclonal antibody (mAb), vaccine, and geography.

The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea. The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin, and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax, and Cervarix.

Under geographic analysis, the report identifies and analyses the biological drugs market size and provides forecasts for the markets in North America, Europe, Asia and Rest of the World (RoW). Major players operating in the biological drugs market are Pfizer Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Baxter International Inc., and Biogen Idec. These companies have been profiled based on attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts